H.C. Wainwright lowered the firm’s price target on Neuphoria Therapeutics (NEUP) to $7 from $21 and keeps a Buy rating on the shares. The firm says the company is “caught between a rock and a hard place right now.” With the Phase 3 social anxiety disorder failure, Neuphoria’s risk profile “has increased significantly,” the anlayst tells investors in a research note. However, the firm says the positive Phase 2b post-traumatic stress disorder data still provides value to the company.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUP:
- Neuphoria Therapeutics responds to Lynx1’s revised indication of interest
- Neuphoria Therapeutics ‘exposes false narratives’ responding to Lynx1
- Neuphoria Therapeutics urges stockholders to vote for company nominees
- Neuphoria initiates strategic review, confirms receipt of indication of interest
- Neuphoria Therapeutics Declares Dividend Rights Plan